Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin 4 mg for BPH associated with chronic prostatitis/chronic pelvic pain syndrome
KCT0004249Phase 4Not yet recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of terazosin in benign prostatic hyperplasia (BPH), Prostatodynia (CP/CPPS), sponsored by Il-Yang Pharmaceutical. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
terazosin
03
Conditions
benign prostatic hyperplasia (BPH)Prostatodynia (CP/CPPS)
Beyond the preview
Go deeper on KCT0004249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004249.